RU2138500C1 - Производные ксантина и их фармакологически переносимые соли - Google Patents

Производные ксантина и их фармакологически переносимые соли Download PDF

Info

Publication number
RU2138500C1
RU2138500C1 RU95109100A RU95109100A RU2138500C1 RU 2138500 C1 RU2138500 C1 RU 2138500C1 RU 95109100 A RU95109100 A RU 95109100A RU 95109100 A RU95109100 A RU 95109100A RU 2138500 C1 RU2138500 C1 RU 2138500C1
Authority
RU
Russia
Prior art keywords
carbon atoms
group
substituted
alkyl
formula
Prior art date
Application number
RU95109100A
Other languages
English (en)
Russian (ru)
Other versions
RU95109100A (ru
Inventor
Кюфнер-Мюль Ульрике
Энзингер Хельмут
Мирау Йоахим
Кун Франц-Йозеф
Лер Эрих
Мюллер Энцио
Original Assignee
Берингер Ингельхайм КГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Берингер Ингельхайм КГ filed Critical Берингер Ингельхайм КГ
Publication of RU95109100A publication Critical patent/RU95109100A/ru
Application granted granted Critical
Publication of RU2138500C1 publication Critical patent/RU2138500C1/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU95109100A 1992-08-10 1993-08-05 Производные ксантина и их фармакологически переносимые соли RU2138500C1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE4226371 1992-08-10
DEP4226371.9 1992-08-10
DE4238423 1992-11-13
DEP4238423.0 1992-11-13
PCT/EP1993/002077 WO1994003456A1 (de) 1992-08-10 1993-08-05 Unsymmetrisch substituierte xanthine mit adenosinantagonistischen eigenschaften

Publications (2)

Publication Number Publication Date
RU95109100A RU95109100A (ru) 1996-12-27
RU2138500C1 true RU2138500C1 (ru) 1999-09-27

Family

ID=25917371

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95109100A RU2138500C1 (ru) 1992-08-10 1993-08-05 Производные ксантина и их фармакологически переносимые соли

Country Status (21)

Country Link
US (1) US5719279A (US20050026921A1-20050203-C00045.png)
EP (1) EP0654033A1 (US20050026921A1-20050203-C00045.png)
JP (1) JPH08500344A (US20050026921A1-20050203-C00045.png)
KR (1) KR950702988A (US20050026921A1-20050203-C00045.png)
CN (1) CN1043348C (US20050026921A1-20050203-C00045.png)
AU (1) AU681348B2 (US20050026921A1-20050203-C00045.png)
BG (1) BG62618B1 (US20050026921A1-20050203-C00045.png)
CA (1) CA2140883A1 (US20050026921A1-20050203-C00045.png)
CZ (1) CZ286459B6 (US20050026921A1-20050203-C00045.png)
FI (1) FI950542A (US20050026921A1-20050203-C00045.png)
HU (1) HUT65734A (US20050026921A1-20050203-C00045.png)
IL (1) IL106624A (US20050026921A1-20050203-C00045.png)
MX (1) MX9304819A (US20050026921A1-20050203-C00045.png)
NZ (1) NZ254804A (US20050026921A1-20050203-C00045.png)
PL (1) PL176389B1 (US20050026921A1-20050203-C00045.png)
RU (1) RU2138500C1 (US20050026921A1-20050203-C00045.png)
SG (1) SG55038A1 (US20050026921A1-20050203-C00045.png)
SK (1) SK18595A3 (US20050026921A1-20050203-C00045.png)
TW (1) TW252044B (US20050026921A1-20050203-C00045.png)
UA (1) UA46697C2 (US20050026921A1-20050203-C00045.png)
WO (1) WO1994003456A1 (US20050026921A1-20050203-C00045.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014684B1 (ru) * 2001-09-06 2010-12-30 Байоджен Айдек Ма Инк. Способы лечения легочных заболеваний

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW252044B (US20050026921A1-20050203-C00045.png) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
GB9415529D0 (en) 1994-08-01 1994-09-21 Wellcome Found Phenyl xanthine derivatives
AU4527896A (en) * 1994-12-13 1996-07-03 Euro-Celtique S.A. Aryl thioxanthines
ATE247655T1 (de) 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
US5864037A (en) 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
GB9623859D0 (en) * 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
WO1999031101A1 (en) * 1997-12-17 1999-06-24 University Of South Florida Adenosine receptor antagonists with improved bioactivity
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2336967C (en) 1998-07-10 2010-06-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
EP1775297A3 (en) 1999-11-12 2008-12-03 Biogen Idec MA Inc. Adenosine receptor antagonists and methods of making and using the same
CZ20021614A3 (cs) * 1999-11-12 2002-07-17 Biogen, Inc. Polycykloalkylpuriny jako antagonisty adenosinového receptoru
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
ATE336492T1 (de) 2000-01-14 2006-09-15 Us Gov Health & Human Serv Methonocarbacycloalkylanaloga von nucleosiden
ATE353900T1 (de) * 2001-02-24 2007-03-15 Boehringer Ingelheim Pharma Xanthinderivate, deren herstellung und deren verwendung als arzneimittel
EP1521584A1 (en) 2002-06-17 2005-04-13 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7202252B2 (en) * 2003-02-19 2007-04-10 Endacea, Inc. A1 adenosine receptor antagonists
NZ543109A (en) 2003-04-25 2008-06-30 Novacardia Inc Method of improved diuresis in individuals with impaired renal function
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
WO2004110379A2 (en) * 2003-06-09 2004-12-23 Endacea, Inc. A1 adenosine receptor antagonists
US7566707B2 (en) 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10355304A1 (de) * 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US8071583B2 (en) * 2006-08-08 2011-12-06 Boehringer Ingelheim International Gmbh Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
CA2709772A1 (en) 2007-12-21 2009-07-09 Endacea, Inc. A1 adenosine receptor antagonists
US7928259B2 (en) * 2008-02-12 2011-04-19 Frx Polymers, Inc. Diaryl alkylphosphonates and methods for preparing same
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
JP5334511B2 (ja) * 2008-09-22 2013-11-06 日本精化株式会社 化粧料
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
BRPI1013561A8 (pt) * 2009-03-26 2015-09-22 Mapi Pharma Ltd processo para a preparação de alogliptina
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
RU2643336C1 (ru) * 2016-10-03 2018-01-31 Общество с Ограниченной Ответственностью "Компания "ЭЛТА" СРЕДСТВО, ПРОЯВЛЯЮЩЕЕ АНТИТРОМБОТИЧЕСКИЙ ЭФФЕКТ ПОСРЕДСТВОМ БЛОКИРОВАНИЯ РЕЦЕПТОРОВ ТРОМБОЦИТОВ ГП IIb-IIIa (ВАРИАНТЫ)
CN109796453A (zh) * 2019-02-12 2019-05-24 南京纽邦生物科技有限公司 一种1,7-二甲基黄嘌呤的制备方法
EP4229059A1 (en) 2020-10-15 2023-08-23 Rheinische Friedrich-Wilhelms-Universität Bonn 3-substituted xanthine derivatives as mrgprx4 receptor modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
US4772607A (en) * 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US4783530A (en) * 1986-11-13 1988-11-08 Marion Laboratories, Inc. 8-arylxanthines
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5032593A (en) * 1988-07-01 1991-07-16 Marion Merrell Dow Inc. Method of treating bronchoconstriction with 1,3-unsymmetrical straight chain alkyl-substituted 8-phenylxanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
EP0559893B1 (en) * 1990-10-18 1999-02-03 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivative
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
TW252044B (US20050026921A1-20050203-C00045.png) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5366977A (en) * 1992-09-29 1994-11-22 The United States Of America, As Represented By The Department Of Health And Human Services Method of treating cystic fibrosis using 8-cyclopentyl-1,3-dipropylxanthine or xanthine amino congeners

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA014684B1 (ru) * 2001-09-06 2010-12-30 Байоджен Айдек Ма Инк. Способы лечения легочных заболеваний

Also Published As

Publication number Publication date
NZ254804A (en) 1997-01-29
IL106624A0 (en) 1993-12-08
CZ286459B6 (en) 2000-04-12
RU95109100A (ru) 1996-12-27
BG62618B1 (bg) 2000-03-31
FI950542A0 (fi) 1995-02-08
BG99489A (bg) 1996-01-31
IL106624A (en) 1999-01-26
SG55038A1 (en) 1998-12-21
WO1994003456A1 (de) 1994-02-17
HUT65734A (en) 1994-07-28
JPH08500344A (ja) 1996-01-16
SK18595A3 (en) 1995-07-11
US5719279A (en) 1998-02-17
AU4707193A (en) 1994-03-03
AU681348B2 (en) 1997-08-28
CN1043348C (zh) 1999-05-12
CN1086818A (zh) 1994-05-18
MX9304819A (es) 1994-02-28
HU9302302D0 (en) 1993-10-28
PL176389B1 (pl) 1999-05-31
CZ34895A3 (en) 1995-10-18
PL307397A1 (en) 1995-05-15
KR950702988A (ko) 1995-08-23
UA46697C2 (uk) 2002-06-17
CA2140883A1 (en) 1994-02-17
FI950542A (fi) 1995-02-08
TW252044B (US20050026921A1-20050203-C00045.png) 1995-07-21
EP0654033A1 (de) 1995-05-24

Similar Documents

Publication Publication Date Title
RU2138500C1 (ru) Производные ксантина и их фармакологически переносимые соли
AU2019213425B2 (en) Autotaxin inhibitor compounds
US5470867A (en) Imidazoles and their salts having antagonistic activity to angiotesin II recetors
KR100526094B1 (ko) Ｐｄｅ5 저해제로서 8-퀴놀린크산틴 및8-이소퀴놀린크산틴 유도체
EP1911755B1 (en) Benzoimidazole compound capable of inhibiting prostaglandin d synthetase
JP4685243B2 (ja) ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
OA12147A (en) PyrroloÄ2,3dÜpyrimidine compositions and their use.
JP2003506375A (ja) チロシンタンパク質キナーゼｓｙｋのプリン誘導体阻害剤
CA2674875A1 (en) Purine derivatives
US6187780B1 (en) Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
US4782055A (en) Imidazopyridine compounds useful in the treatment of ulcers
MX2008015954A (es) 8-[6-amino-3-piridil]xantinas sustituidas.
US6878716B1 (en) Compounds specific to adenosine A1 receptor and uses thereof
RU2295525C2 (ru) Амидозамещенные производные ксантина, обладающие ингибирующим действием фосфоенолпируваткарбоксикиназы (фепкк), способ их получения, фармацевтическая композиция и применение
CN1219936A (zh) 新的三唑并嘌呤、其制备方法及其作为药品的用途
CA2328264A1 (en) Novel asymmetrically substituted xanthine derivatives, method for producing them and their use as medicaments with an adenosine-antagonistic effect
DE4325254A1 (de) Unsymmetrisch substituierte Xanthine
US20090143375A1 (en) Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents
WO2004076414A2 (en) Novel compounds
DK158725B (da) N-phenyl-oxamsyrederivater og farmaceutiske praeparater indeholdende disse
MX2008000657A (es) Compuesto benzoimidazol capaz de inhibir prostaglandina d sintetasa.